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To the Editor: Resistance of Mycobacterium tuberculosis to the
commonly used antibiotics in national tuberculosis
programmes (NTPs) is a growing concern in many parts of the
world.1 Nevertheless there is much anecdotal, but little
published, evidence that drug resistance is becoming an
important barrier to effective TB control.2 In Zimbabwe the
only routine source of data on drug resistance that is going
further than individual case management is that of the national
TB reference laboratory. This institute is performing routine
drug susceptibility testing on sputum samples for the whole
country. According to the NTBP guidelines, this test is only
done on specific indications, i.c. when a sputum-positive
patient has not converted to negative after 2 months of
intensive antituberculosis chemotherapy.3
To get an idea of the prevalence of single drug resistance, we
performed susceptibility testing on a sample of 134 consecutive
TB culture-positive patients, diagnosed between September
2000 and September 2001 at Gweru Provincial Hospital. These
patients were selected for a study that examined the
characteristics of different laboratory methods, and the
accuracy of the diagnosis in routine circumstances. The results
are described elsewhere;4 this letter focuses on the
susceptibility testing. 
Two samples (1.5%) were resistant to isoniazid and
streptomycin, 2 were resistant to streptomycin only, and 1
(0.7%) was resistant to ethambutol only. None of these patients
had received TB treatment before, they converted when
sputum was checked after 2 months, and they were cured after
the continuation phase. There were 4 men and 1 woman. No
resistance to rifampicin was detected. Among the 134 patients,
7 (5.2%) had taken TB drugs before, be it a complete course (5
‘relapses’), or a partial course (2 ‘defaulters’). TB cultures of
these patients were fully sensitive to the tested drugs. Quality
control of the resistant samples was provided by the
Department of Medical Biochemistry of Stellenbosch
University, South Africa. All resistant samples detected in this
study were double checked using the minimal inhibitory
concentration method for isoniazid and rifampicin resistance.
The RpoB gene (linked to rifampicin resistance) and the KatG
gene (linked to isoniazid resistance) were sequenced to look for
genomic mutations. A mutation in the KatG gene codon 315
was detected in only 1 isoniazid-resistant sample, suggesting
that the resistance of the second isoniazid-resistant sample was
associated with mutations in other genes.
Drug resistance testing has been recommended by the World
Health Organisation (WHO) for monitoring and guiding TB
treatment programmes. Initial or acquired resistance is
considered a key indicator for programme performance.
Resistance is seen as a man-made problem, resulting from
inadequate treatment regimens or poor compliance. The results
of this study are reassuring in the sense that no case of multi-
drug resistance (MDR) was detected among this series of
patients, neither clinically nor microbiologically. The levels of
initial resistance are far below the arbitrary threshold of 5%
that is considered the cut-off point to question treatment
regimens. No single-drug resistance was detected among
relapse cases and no resistance in particular was detected
against rifampicin, the most important drug to prevent failures
or relapses. These results suggest that the TB programme was
performing well at the time of the study and that the risk of
developing a problem of MDR with public health implications
is still low in this province. 
It must be made clear, however, that this sample was not,
and was not meant to be, representative of the whole country.
It is recommended that a resistance surveillance programme be
set up covering the whole country, based on randomised
sampling techniques as described by the WHO. This would
give a more accurate idea of resistance patterns throughout the
country, and if done on a regular basis, on trends over time.
Indirectly, it would also be a tool to monitor the NTBP
performance. As MDR strains are inevitably preceded by
single-drug resistant strains, monitoring of the latter could
provide vital information on the risk of developing MDR in
this community.  
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